News

Patients taking a 350 mg dose of the drug demonstrated a 24% reduction, while patients who took the 700 mg dose showed a 30% reduction compared to a

DiCE is a privately-held startup, which focuses on the development of next-generation methods to small molecule drug discovery. The collaboration will see Sanofi pay an initial $50m to

A recent survey commissioned by the makers of Children’s Flonase Allergy Relief revealed that a majority of parents of young children with seasonal allergies tend to limit their

Repros is seeking the enclomiphene marketing authorization for Europe through a central filing which is valid in all European Union and European Economic Area countries, i.e. 31 countries

The procedure, involving a single injection of hRPC cells under the retina, was conducted at Massachusetts Eye and Ear in Boston, a teaching affiliate of Harvard Medical School

RPL554 is a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule, currently in development as a nebulised treatment for acute exacerbations in

After completion of the acquisition, including the agreed upon transition period, Orexigen will hold all rights to Contrave in almost all territories globally. The companies have agreed to

The approval was based on its bioequivalence to the standard melphalan formulation (Alkeran) in a phase 2 clinical study. Evomela has been granted Orphan Drug Designation by the

The treatment is for patients with locally advanced or metastatic urothelial carcinoma (mUC) who had disease progression during or after platinum-based chemotherapy in the metastatic setting, or whose